Methods We conducted a retrospective analysis of MIBC patients assessed by a
multidisciplinary team at the Juravinski Cancer Centre from 2010–2016. Patients underwent …

Complete transurethral resection of bladder tumor (TURBT) is the initial procedure of choice
for non–muscle-invasive bladder cancer, but its quality is far from optimal in clinical practice …

Purpose: Patients with muscle invasive bladder cancer (MIBC) of variant histology have a
poor prognosis. It is unclear if neoadjuvant chemotherapy prior to radical cystectomy is …

Radical cystectomy with pelvic lymph node dissection is currently viewed as the standard of
care for muscle-invasive bladder cancer, with 5-year overall survival rates in contemporary …

Simple Summary Bladder cancer is one of the leading causes of death worldwide. About
75% of patients initially present with non-muscle-invasive disease, while the rest presents …

Purpose We investigated the characteristics and outcomes of patients with muscle invasive
bladder cancer treated with transurethral resection plus chemotherapy alone in a large …

Study Type–Therapy (case series) Level of Evidence 4 What's known on the subject? and
What does the study add? Systemic chemotherapy for muscle‐invasive bladder cancer is …

BACKGROUND Practice guidelines recommend neoadjuvant chemotherapy (NACT) for
bladder cancer. However, the evidence in support of adjuvant chemotherapy (ACT) is less …

Simple Summary Neoadjuvant chemotherapy followed by radical cystectomy is the
recommended standard of care for muscle-invasive bladder cancer patients who are eligible …

Response classification after neoadjuvant chemotherapy in muscle-invasive bladder
carcinoma is based on the TNM stage at radical cystectomy. We recently showed that …